Related Experiment Video

Updated: Jun 3, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Dyslipidemia related to antiretroviral therapy

Vicente Estrada1, Joaquín Portilla

  • 1Department of Infectious Diseases, Hospital Clínico San Carlos, Madrid, Spain. vestrada.hcsc@salud.madrid.org

AIDS Reviews
|March 18, 2011
PubMed

Insights

Dyslipidemia, a common issue in HIV patients, stems from the virus, host factors, and antiretroviral therapy. Managing these lipid disorders is crucial for reducing cardiovascular risk in HIV care.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Dyslipidemia is prevalent in patients with human immunodeficiency virus (HIV) infection.
  • It is a significant cardiovascular risk factor, influenced by viral, host, and antiretroviral treatment (ART) factors.
  • HIV infection and ART are linked to accelerated atherosclerosis and increased myocardial infarction rates.

Purpose of the Study:

  • To review the pathogenic mechanisms of dyslipidemia in HIV patients undergoing ART.
  • To evaluate the impact of current antiretroviral drugs on lipid profiles.
  • To outline current recommendations for managing dyslipidemia in this population.

Main Methods:

  • Literature review of pathogenic mechanisms of dyslipidemia in HIV.
  • Analysis of the effects of various antiretroviral drugs on lipid profiles.
  • Synthesis of current clinical guidelines for dyslipidemia management in HIV.

Main Results:

  • Dyslipidemia pathogenesis in HIV is multifactorial, involving viral, host, and ART components.
  • Antiretroviral drugs have varying effects on lipid profiles, contributing to dyslipidemia.
  • Accelerated atherosclerosis and increased cardiovascular events are associated with HIV and its treatment.

Conclusions:

  • Dyslipidemia management is a clinical priority for HIV-infected patients.
  • Recommendations include controlling cardiovascular risk factors, selecting ART with favorable lipid profiles, and using lipid-lowering drugs when necessary.
  • A comprehensive approach is needed to mitigate cardiovascular risks in HIV patients with dyslipidemia.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...